Published in J Exp Med on July 04, 2005
Exosomes as a tumor immune escape mechanism: possible therapeutic implications. J Transl Med (2008) 1.28
Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway. Cancer Cell (2011) 1.22
MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. J Exp Med (2008) 1.13
Receptor-mediated phagocytosis elicits cross-presentation in nonprofessional antigen-presenting cells. Proc Natl Acad Sci U S A (2009) 1.05
Matched rabbit monoclonal antibodies against αv-series integrins reveal a novel αvβ3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors. Biol Open (2012) 0.91
Matrix metalloproteinase-2 promotes αvβ3 integrin-mediated adhesion and migration of human melanoma cells by cleaving fibronectin. PLoS One (2012) 0.89
Osteopontin is an endogenous modulator of the constitutively activated phenotype of pulmonary adventitial fibroblasts in hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2012) 0.83
Activation of toll-like receptor-2 by endogenous matrix metalloproteinase-2 modulates dendritic-cell-mediated inflammatory responses. Cell Rep (2014) 0.81
Folding of matrix metalloproteinase-2 prevents endogenous generation of MHC class-I restricted epitope. PLoS One (2010) 0.78
Induction of antitumor immunity through xenoplacental immunization. J Transl Med (2006) 0.75
Exposure to Melan-A/MART-126-35 tumor epitope specific CD8(+)T cells reveals immune escape by affecting the ubiquitin-proteasome system (UPS). Sci Rep (2016) 0.75
CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy. Hum Vaccin Immunother (2015) 0.75
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science (1994) 12.83
Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 12.29
Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 9.51
Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods (1989) 9.42
Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (1994) 6.73
Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell (1996) 6.52
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1993) 6.47
A membrane protein complex mediates retro-translocation from the ER lumen into the cytosol. Nature (2004) 6.37
Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature (1980) 5.84
Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med (1999) 5.55
A membrane protein required for dislocation of misfolded proteins from the ER. Nature (2004) 5.39
Spatio-temporal images of growth-factor-induced activation of Ras and Rap1. Nature (2001) 4.83
Endoplasmic reticulum-mediated phagocytosis is a mechanism of entry into macrophages. Cell (2002) 4.52
Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res (1998) 4.39
Biogenesis of phagolysosomes proceeds through a sequential series of interactions with the endocytic apparatus. J Cell Biol (1994) 4.26
ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature (2003) 4.18
Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med (2000) 3.32
Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell (1998) 2.89
Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science (1999) 2.62
Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med (1999) 2.62
Compartmentalization of bacterial antigens: differential effects on priming of CD8 T cells and protective immunity. Cell (1998) 2.59
Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J Biol Chem (2000) 2.18
Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med (1998) 2.11
A giant protease with potential to substitute for some functions of the proteasome. Science (1999) 2.08
Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol (2004) 1.97
Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc Natl Acad Sci U S A (2000) 1.76
Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Lett (1996) 1.63
A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res (2001) 1.49
Conformational constraints in protein degradation by the 20S proteasome. Nat Struct Biol (1995) 1.42
A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med (1996) 1.42
Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways. Mol Immunol (2002) 1.31
Molecular role(s) for integrins in human melanoma invasion. Cancer Metastasis Rev (1999) 1.21
T-cell responses of vaccinated cancer patients. Curr Opin Immunol (2003) 1.18
Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation. Cancer Res (2003) 1.14
Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother (2002) 1.12
Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. Nat Rev Cancer (2002) 1.12
Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes. Eur J Immunol (1993) 1.08
Identification of a negatively charged peptide motif within the catalytic domain of progelatinases that mediates binding to leukocyte beta 2 integrins. J Biol Chem (2003) 1.03
Coexpression of integrin alpha(v)beta3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. J Invest Dermatol (2000) 1.00
Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunol Immunother (2002) 1.00
Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation. J Immunol (1999) 0.95
A processed pseudogene codes for a new antigen recognized by a CD8(+) T cell clone on melanoma. J Exp Med (2000) 0.92
Selective involvement of proteasomes and cysteine proteases in MHC class I antigen presentation. J Immunol (1997) 0.92
Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription. J Immunol (1997) 0.91
Melanoma-associated antigens recognized by cytotoxic T lymphocytes. APMIS (1998) 0.90
MHC class I antigen processing regulated by cytosolic proteolysis-short cuts that alter peptide generation. Mol Immunol (2002) 0.87
Development and characterization of novel potent and stable inhibitors of endopeptidase EC 3.4.24.15. Biochem J (2000) 0.87
Matrix metalloproteinases of normal human tissues. Biochemistry (Mosc) (2001) 0.81
Long-term inhibition of glioma growth by systemic administration of human PEX. J Neurosurg Sci (2003) 0.78
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med (2002) 5.58
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol (2003) 2.83
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol (2004) 2.50
A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med (2007) 2.41
Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. J Invest Dermatol (2009) 1.87
Defining early mycosis fungoides. J Am Acad Dermatol (2005) 1.78
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol (2013) 1.67
Brain magnetic resonance imaging in patients with Cowden syndrome. Medicine (Baltimore) (2005) 1.50
Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol (2008) 1.47
V gamma 9V delta 2 T cell response to colon carcinoma cells. J Immunol (2005) 1.45
A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol (2009) 1.26
Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway. Cancer Cell (2011) 1.22
Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol (2006) 1.20
Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med (2013) 1.15
Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J Immunol (2005) 1.13
MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. J Exp Med (2008) 1.13
Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother (2002) 1.12
Long-lasting cross-presentation of tumor antigen in human DC. Eur J Immunol (2009) 1.09
Gluten intolerance and skin diseases. Eur J Dermatol (2006) 1.08
Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. J Immunol (2003) 1.07
Dominant TCR V alpha usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens. Eur J Immunol (2002) 1.07
HLA-E/β2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression. Int J Cancer (2012) 1.00
Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunol Immunother (2002) 1.00
A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J Immunol (2002) 0.99
Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother (2007) 0.95
Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients. Cancer Immunol Immunother (2006) 0.94
Infantile acne: a retrospective study of 16 cases. Pediatr Dermatol (2008) 0.94
In vitro modulation of TLR-2, CD1d and IL-10 by adapalene on normal human skin and acne inflammatory lesions. Exp Dermatol (2007) 0.92
ERK-regulated differential expression of the Mitf 6a/b splicing isoforms in melanoma. Pigment Cell Melanoma Res (2009) 0.91
A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes. Cancer Immunol Immunother (2008) 0.89
Apoptotic body-loaded dendritic cells efficiently cross-prime cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/MART-1 antigen. Int J Cancer (2002) 0.89
Interstitial brachytherapy of periorificial skin carcinomas of the face: a retrospective study of 97 cases. Int J Radiat Oncol Biol Phys (2005) 0.88
Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy. Eur J Immunol (2010) 0.88
Targeted melanoma prevention intervention: a cluster randomized controlled trial. Ann Fam Med (2014) 0.87
Melanomas Associated With Blue Nevi or Mimicking Cellular Blue Nevi: Clinical, Pathologic, and Molecular Study of 11 Cases Displaying a High Frequency of GNA11 Mutations, BAP1 Expression Loss, and a Predilection for the Scalp. Am J Surg Pathol (2016) 0.86
Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells. J Med Chem (2007) 0.86
Large scale expansion of gamma 9 delta 2 T lymphocytes: Innacell gamma delta cell therapy product. J Immunol Methods (2007) 0.86
Expression of CD94/NKG2-A on human T lymphocytes is induced by IL-12: implications for adoptive immunotherapy. J Immunol (2002) 0.86
Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles. Clin Immunol (2006) 0.86
HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells. J Immunol (2012) 0.85
PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting. Cancer Immunol Immunother (2007) 0.85
Rituximab for primary cutaneous diffuse large B-cell lymphoma-leg type. Eur J Dermatol (2010) 0.84
Tumor-reactive CD4+ CD8αβ+ CD103+ αβT cells: a prevalent tumor-reactive T-cell subset in metastatic colorectal cancers. Int J Cancer (2010) 0.84
Large scale expansion of Vgamma9Vdelta2 T lymphocytes from human peripheral blood mononuclear cells after a positive selection using MACS "TCR gamma/delta+ T cell isolation kit". J Immunol Methods (2009) 0.84
Increased frequency of nonconventional double positive CD4CD8 alphabeta T cells in human breast pleural effusions. Int J Cancer (2009) 0.84
Tissue prognostic markers for adoptive immunotherapy in melanoma. Eur J Dermatol (2007) 0.84
Melanoma incidence and patient compliance in a targeted melanoma screening intervention. One-year follow-up in a large French cohort of high-risk patients. Eur J Gen Pract (2014) 0.83
Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients. Cancer Immunol Immunother (2015) 0.83
CD13 and TCR clone: markers of early mycosis fungoides. Acta Derm Venereol (2007) 0.82
Efficacy of cetuximab in the treatment of squamous cell carcinoma. J Dermatolog Treat (2013) 0.82
Inducible Hsp70 as target of anticancer immunotherapy: Identification of HLA-A*0201-restricted epitopes. Int J Cancer (2004) 0.82
Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study. Melanoma Res (2008) 0.82
Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J Immunol (2003) 0.82
MELOE-1 antigen contains multiple HLA class II T cell epitopes recognized by Th1 CD4+ T cells from melanoma patients. PLoS One (2012) 0.82
Double positive CD4CD8 alphabeta T cells: a new tumor-reactive population in human melanomas. PLoS One (2010) 0.82
A spliced antigenic peptide comprising a single spliced amino acid is produced in the proteasome by reverse splicing of a longer peptide fragment followed by trimming. J Immunol (2014) 0.82
Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. Cancer Gene Ther (2002) 0.81
HLA-E-restricted cross-recognition of allogeneic endothelial cells by CMV-associated CD8 T cells: a potential risk factor following transplantation. PLoS One (2012) 0.81
An additional ORF on meloe cDNA encodes a new melanoma antigen, MELOE-2, recognized by melanoma-specific T cells in the HLA-A2 context. Cancer Immunol Immunother (2010) 0.80
The melanoma antigens MELOE-1 and MELOE-2 are translated from a bona fide polycistronic mRNA containing functional IRES sequences. PLoS One (2013) 0.80
Stimulatory effect of boron and manganese salts on keratinocyte migration. Acta Derm Venereol (2004) 0.79
A HLA-Cw*0701 restricted Melan-A/MART1 epitope presented by melanoma tumor cells to CD8+ tumor infiltrating lymphocytes. Cancer Immunol Immunother (2007) 0.79
A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes. Cancer Immunol Immunother (2007) 0.79
Covalent modification of a melanoma-derived antigenic peptide with a natural quinone methide. Preliminary chemical, molecular modelling and immunological evaluation studies. Mol Biosyst (2006) 0.78
Folding of matrix metalloproteinase-2 prevents endogenous generation of MHC class-I restricted epitope. PLoS One (2010) 0.78
Synthesis of glycocluster-tumor antigenic peptide conjugates for dendritic cell targeting. Bioconjug Chem (2007) 0.78
Modulation in vitro of keratinocyte integrins by interferon-alpha and interferon-gamma. Int J Dermatol (2002) 0.78
Perioperative interstitial brachytherapy for recurrent keloid scars. Plast Reconstr Surg (2009) 0.78
Interstitial brachytherapy for lower lip carcinoma: global assessment in a retrospective study of 89 cases. Head Neck (2012) 0.78
Zinc gluconate is an agonist of peroxisome proliferator-activated receptor-α in the epidermis. Exp Dermatol (2012) 0.78
Is antigen specificity the key to efficient adoptive T-cell therapy? Immunotherapy (2011) 0.78
CD8(+) T lymphocytes reactive against Epstein-Barr virus antigens in skin lesions of a patient with Sézary syndrome. J Am Acad Dermatol (2005) 0.78
A new tyrosinase epitope recognized in the HLA-B*4002 context by CTL from melanoma patients. Cancer Immunol Immunother (2008) 0.77